*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
My team has been following clinical-stage biotech company $LCTX for the past few months. $LCTX pipeline looks very promising. We believe that current price levels are undermining the companies potential. We entered $LCTX on 5/14/21 at $2.23 per share and have been holding ever since. Following its correction from its 52-week high of $3.13 $LCTX now sits at $2.80 per share.
My team averaged up on our $LCTX position this morning at $2.70 per share and intend to take profit at $4.20.
ORIGINAL ENTRY: $2.23
AVERAGING UP AT: $2.70
TAKE PROFIT: $4.20
STOP PROFIT LOSS: $2.50
If you want to see more, please like and follow us @SimplyShowMeTheMoney
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
My team has been following clinical-stage biotech company $LCTX for the past few months. $LCTX pipeline looks very promising. We believe that current price levels are undermining the companies potential. We entered $LCTX on 5/14/21 at $2.23 per share and have been holding ever since. Following its correction from its 52-week high of $3.13 $LCTX now sits at $2.80 per share.
My team averaged up on our $LCTX position this morning at $2.70 per share and intend to take profit at $4.20.
ORIGINAL ENTRY: $2.23
AVERAGING UP AT: $2.70
TAKE PROFIT: $4.20
STOP PROFIT LOSS: $2.50
If you want to see more, please like and follow us @SimplyShowMeTheMoney